Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - clomifene citrate, quantity: 50 mg - tablet, uncoated - excipient ingredients: sucrose; lactose monohydrate; maize starch; magnesium stearate; pregelatinised maize starch; iron oxide yellow - indications as at 1 january 1991: clomid is indicated for the treatment of ovarian failure in carefully selected infertile women who wish to become pregnant.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - clomifene citrate, quantity: 50 mg - tablet, uncoated - excipient ingredients: magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; lactose monohydrate; maize starch; povidone - indications: clomiphene citrate is indicated in the treatment of ovulatory failure in patients desiring pregnancy, whose partners have adequate sperm and who have potentially functional hypothalamic-hypophyseal ovarian systems and adequate endogenous oestrogens. impediments to this goal must be excluded or adequately treated before beginning therapy. administration of clomiphene is indicated only in patients with demonstrated ovulatory dysfunction and in whom the following condition apply: 1. demonstration of normal liver function 2. physiological indications of normal or near normal endogenous oestrogen levels should be present (as estimated from vaginal smears, endometrial biopsy, assay of urinary or serum oestrogen or from bleeding in response to progesterone). reduced oestrogen levels, while less favourable, do not prevent successful therapy. 3. clomiphene citrate is not effective in patients with primary pituitary or ovarian failure. it cannot substitute for appropriate therapy of other disturbances leading to ovulatory dysfunction, e.g. diseases of the thyroid or adrenals. 4. patients with abnormal uterine bleeding should be thoroughly evaluated prior to initiating clomiphene therapy. it is most important that neoplastic lesions are detected.

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - clomiphene citrate - tablet - 50 milligram(s) - ovulation stimulants, synthetic; clomifene

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - clomifene citrate - oral tablet - 50mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

wockhardt uk ltd - clomifene citrate - oral tablet - 50mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - clomifene citrate - oral tablet - 50mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

dowelhurst ltd - clomifene citrate - oral tablet - 50mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - clomifene citrate - oral tablet - 50mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

phoenix healthcare distribution ltd - clomifene citrate - oral tablet - 50mg

Australia - English - Department of Health (Therapeutic Goods Administration)

orion pharma (aus) pty limited - toremifene citrate, quantity: 88.5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; colloidal anhydrous silica; sodium starch glycollate; microcrystalline cellulose; magnesium stearate; povidone; maize starch - for the first line treatment of hormone-dependent metastatic breast cancer in postmenopausal women. it is not recommended for patients with oestrogen receptor negative tumours.